Enspryng Disease Interactions
There are 3 disease interactions with Enspryng (satralizumab).
Satralizumab (applies to Enspryng) active hepatitis B
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
Satralizumab is contraindicated in patients with active hepatitis B infection. All patients should be screened for hepatitis B before treatment initiation.
Satralizumab (applies to Enspryng) tuberculosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent
Satralizumab is contraindicated in patients with active or untreated latent tuberculosis. All patients should be screened for tuberculosis before treatment initiation and monitored for the development of symptoms or signs of tuberculosis during treatment, even if the initial testing is negative.
Satralizumab (applies to Enspryng) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Treatment with satralizumab can increase the risk of serious infections. Treatment should be delayed until any active infection is treated and resolved.
Switch to professional interaction data
Enspryng drug interactions
There are 351 drug interactions with Enspryng (satralizumab).
Report options
More about Enspryng (satralizumab)
- Enspryng consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) or ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Inebilizumab
Inebilizumab is used to treat adults with NMOSD (neuromyelitis optica spectrum disorder) who are ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
